| 1404 |
National Cancer Institute |
Html |
en |
Sleep Disorders (PDQ®)–Patient Version |
Expert-reviewed information summary about causes and management of sleep disorders in people with cancer. |
| normal sleep patterns | 0.734479 |
| Relaxation therapy | 0.493159 |
| moderate sleep disorders | 0.656166 |
| sleeping problems | 0.484122 |
| PDQ cancer information | 0.646663 |
| sleep medicines | 0.601935 |
| health care team | 0.479673 |
| clinical trials | 0.518721 |
| sleep history | 0.612308 |
| sleep apnea | 0.593611 |
| cancer patient sleeps | 0.499804 |
| cancer information summary | 0.579061 |
| clinical trial | 0.483994 |
| breast cancer prevention | 0.483786 |
| good sleep habits | 0.703452 |
| cancer patients | 0.541537 |
| treatment instructions | 0.483188 |
| sleep problems | 0.627478 |
| mild sleep disorders | 0.656367 |
| NCI’s PDQ | 0.480637 |
| NCI PDQ cancer | 0.525102 |
| Common cancer treatments | 0.495476 |
| sleep disorder clinic | 0.627008 |
| deep sleep | 0.635758 |
|
| treatment | 0.54776 |
| cancer prevention | 0.48441 |
| lighter sleep | 0.598128 |
| Cancer Information Service | 0.493437 |
| REM sleep | 0.662129 |
| sleep | 0.949433 |
| good night | 0.507447 |
| National Cancer Institute | 0.585654 |
| sleep repeat | 0.634943 |
| light sleep | 0.635787 |
| Palliative Care Editorial | 0.524141 |
| new treatment | 0.481731 |
| sleep disorders | 0.849206 |
| sleep restriction | 0.605553 |
| Cancer Care page | 0.486706 |
| Care Editorial Board | 0.525467 |
| health | 0.498616 |
| PDQ summary | 0.533115 |
| sleep disorder | 0.712776 |
| sleep problem | 0.601447 |
| cancer information summaries | 0.498019 |
| comprehensive cancer information | 0.497854 |
| cancer | 0.67715 |
| stimulus control | 0.540953 |
|
CLICK HERE |
| 1493 |
National Cancer Institute |
Html |
en |
Oropharyngeal Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of oropharyngeal cancer. |
| neck radiotherapy | 0.359364 |
| locally advanced head | 0.471621 |
| Engl J Med | 0.53665 |
| American Cancer Society | 0.443811 |
| well-lateralized oropharyngeal cancer | 0.401103 |
| neck radiation therapy | 0.384516 |
| Int J Radiat | 0.508851 |
| neck cancer patients | 0.486158 |
| squamous cell cancer | 0.411067 |
| Radiat Oncol Biol | 0.753309 |
| DeVita VT Jr | 0.383261 |
| Natl Cancer Inst | 0.447951 |
| neck cancers | 0.433823 |
| Clin Cancer Res | 0.390283 |
| radiation therapy | 0.610067 |
| human papillomavirus | 0.44587 |
| smoking-related oropharyngeal cancer | 0.443579 |
| HPV-positive oropharyngeal cancer | 0.448716 |
| et al. | 0.570118 |
| Mendenhall WM | 0.369324 |
| Cancer Genet Cytogenet | 0.359903 |
| Head Neck | 0.484421 |
| index nonoropharyngeal cancer | 0.350094 |
| Oropharyngeal tumors | 0.352557 |
| index oropharyngeal SCC | 0.386084 |
|
| neck SCC | 0.359598 |
| oropharyngeal cancers | 0.476599 |
| HPV-positive oropharyngeal cancers | 0.469127 |
| anterior tonsillar pillar | 0.378606 |
| Cancer Epidemiol Biomarkers | 0.378376 |
| neck squamous cell | 0.377126 |
| head | 0.534685 |
| PUBMED Abstract | 0.462256 |
| early-stage oropharyngeal cancer | 0.392101 |
| Otolaryngol Head Neck | 0.404239 |
| index oropharyngeal cancers | 0.372661 |
| -positive oropharyngeal cancers | 0.363257 |
| neck retinoid chemoprevention | 0.355793 |
| Abstract | 0.60039 |
| Clin Oncol | 0.357598 |
| Oncol Biol Phys | 0.772447 |
| squamous cell carcinomas | 0.385763 |
| primary tumor | 0.372966 |
| field cancerization | 0.370643 |
| neck cancer | 0.957961 |
| neck tumors | 0.340144 |
| oropharyngeal cancer | 0.807108 |
| oropharyngeal SCC | 0.391565 |
| oropharyngeal cancer incidence | 0.417437 |
|
CLICK HERE |
| 1722 |
National Cancer Institute |
Html |
en |
Head and Neck Cancers |
A fact sheet about the risk factors, symptoms, diagnosis, treatment, follow-up, and rehabilitation for cancers of the head and neck. |
| Neck Cancer Epidemiology | 0.558891 |
| cancer treatment | 0.49699 |
| Fraumeni JF Jr. | 0.515344 |
| ongoing clinical trials | 0.479834 |
| squamous cell cancers | 0.517935 |
| nasopharyngeal cancer | 0.510884 |
| paranasal sinuses | 0.510171 |
| aerodigestive tract cancers | 0.489416 |
| Finding NCI-Supported Clinical | 0.476958 |
| American Cancer Society | 0.489371 |
| Cancer Treatment Research | 0.487757 |
| clinical trials | 0.625013 |
| Epstein-Barr virus | 0.482033 |
| neck cancer regions | 0.574118 |
| risk factors | 0.503876 |
| neck cancers | 0.925546 |
| PDQ® cancer treatment | 0.487339 |
| human papillomavirus | 0.505881 |
| HPV-positive oropharyngeal cancer | 0.487463 |
| Cancer Epidemiology Consortium | 0.490318 |
| United States | 0.527186 |
| primary cancer | 0.487797 |
| especially cancers | 0.493827 |
| Cancer fact sheet | 0.485173 |
|
| oropharyngeal cancers | 0.540233 |
| cancer information specialist | 0.512175 |
| Cancer Information Service | 0.478534 |
| neck squamous cell | 0.508691 |
| head | 0.661624 |
| neck primary site | 0.509523 |
| nci-supported clinical trials | 0.526157 |
| Oxford University Press | 0.514213 |
| National Cancer Institute | 0.552506 |
| neck area | 0.499808 |
| nasal cavity | 0.508976 |
| salivary glands | 0.562893 |
| risk factor | 0.525252 |
| Neck Surgery | 0.494318 |
| information specialist online | 0.474123 |
| cancer clinical trials | 0.537911 |
| salivary gland cancer | 0.527021 |
| neck cancer | 0.711277 |
| Clinical Cancer Research | 0.481823 |
| et al | 0.678713 |
| oral cavity | 0.564891 |
| salivary gland cancers | 0.553898 |
| oropharyngeal cancer | 0.508219 |
| oropharyngeal cancer incidence | 0.479853 |
|
CLICK HERE |
| 1821 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores neuroendocrinos de páncreas (tumores de células de los islotes) (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los tumores neuroendocrinos de páncreas (tumores de células de los islotes). |
| Compton CC | 0.337256 |
| Hepatic arterial embolization | 0.325449 |
| Palliative cytoreductive surgery | 0.324641 |
| Surg Oncol Clin | 0.345323 |
| Institute Neuroendocrine Tumor | 0.318293 |
| cases with | 0.339293 |
| cytoreductive surgery versus | 0.325381 |
| Zee S | 0.32021 |
| from neuroendocrine tumors | 0.335775 |
| Curr Gastroenterol Rep | 0.341683 |
| metastatic pancreatic | 0.328587 |
| Sharma D | 0.340566 |
| 7th ed | 0.33713 |
| neuroendocrine tumors after | 0.325028 |
| pancreatic endocrine neoplasms | 0.343793 |
| Pract Res Clin | 0.325267 |
| Prognostic factors | 0.322876 |
| Arch Surg | 0.319413 |
| Kulke MH | 0.322635 |
| peripancreatic neuroendocrine tumors | 0.33552 |
| patients with | 0.809404 |
| Davies K | 0.320348 |
| Database Syst Rev | 0.362811 |
| Conlon KC | 0.392512 |
| metastases from | 0.336216 |
|
| neuroendocrine tumors | 0.991054 |
| Cancer Institute Neuroendocrine | 0.319181 |
| Liver resection versus | 0.326125 |
| unresectable neuroendocrine hepatic | 0.331365 |
| neuroendocrine tumors uncontrolled | 0.335147 |
| Gurusamy KS | 0.342295 |
| Cancer Staging Manual | 0.396035 |
| tumores neuroendocrinos | 0.382461 |
| National Cancer Institute | 0.337396 |
| neuroendocrine tumours | 0.357049 |
| Radioembolization with | 0.325231 |
| Yao JC | 0.326134 |
| using resin 90Y-microspheres | 0.325276 |
| Kwekkeboom DJ | 0.325065 |
| New York | 0.332728 |
| internal radiation microspheres | 0.324552 |
| Clin Oncol | 0.662006 |
| Gastrointest Surg | 0.319657 |
| Hochwald SN | 0.321828 |
| Byrd DR | 0.335399 |
| pancreatic neuroendocrine tumors | 0.490395 |
| with pancreatic | 0.327776 |
| Res Clin Gastroenterol | 0.325221 |
| AJCC Cancer Staging | 0.3987 |
|
CLICK HERE |
| 1996 |
National Cancer Institute |
Html |
es |
Comunicación en la atención del cáncer (PDQ®)–Versión para pacientes |
Resumen de la información revisada por expertos acerca de la comunicación con el paciente de cáncer y sus familiares, que incluye los aspectos distintivos de la comunicación con pacientes de cáncer, los factores que afectan la comunicación y la capacitación en aptitudes para la comunicación. |
| comunicación mejora | 0.843776 |
| familia ayuda | 0.776248 |
| siguientes casos | 0.791497 |
| Physician Data Query | 0.942554 |
| mejores decisiones | 0.835028 |
| siguientes preguntas | 0.768644 |
| suministra información | 0.764377 |
| salud ayuda | 0.830465 |
| médico ayuda | 0.964949 |
|
| National Cancer Institute | 0.757167 |
| siguientes indicaciones | 0.779865 |
| ¿Cuáles archivos | 0.761738 |
| siguientes riesgos | 0.741613 |
| PDQ Comunicación | 0.825783 |
| comunicación ayuda | 0.895884 |
| Instituto Nacional | 0.809598 |
| ¿Cuáles problemas | 0.755893 |
|
CLICK HERE |
| 2106 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de endometrio (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de endometrio. |
| PDQ Tratamiento | 0.669269 |
| general causa sÃntomas | 0.588555 |
| Visuals Online | 0.525614 |
| PDQ Exámenes | 0.596864 |
| cáncer.Los exámenes | 0.641713 |
| Physician Data Query | 0.681868 |
| pequeña cantidad | 0.54391 |
| Estados Unidos | 0.562116 |
| cuello uterino | 0.811632 |
|
| prevención revisa | 0.531482 |
| ecografÃa endovaginal | 0.56717 |
| información ayuda | 0.538498 |
| National Cancer Institute | 0.545187 |
| ecografÃa transvaginal | 0.942856 |
| siguientes riesgos | 0.532576 |
| siguientes sumarios | 0.618993 |
| Instituto Nacional | 0.58569 |
|
CLICK HERE |
| 3432 |
National Cancer Institute |
Html |
es |
Formaldehído y el riesgo de cáncer |
Hoja informativa que trata sobre el formaldehído y su posible relación con el cáncer. Incluye recursos para consultar mayor información. |
| leucemia mieloide | 0.978153 |
| malignancies among workers | 0.549063 |
| TW Alexander Drive | 0.542382 |
| exterior-grade” pressed-wood | 0.527538 |
| cancers among workers | 0.548254 |
| Programa Nacional | 0.567373 |
| largo plazo | 0.580439 |
| Protección Ambiental | 0.673926 |
| Salud Ocupacional | 0.583378 |
| Mortality from | 0.576068 |
| Instituto Nacional | 0.645898 |
| Indoor Air | 0.527731 |
| pequeñas cantidades | 0.52948 |
| Lubin JH | 0.573228 |
| posibles efectos | 0.584035 |
| Estados Unidos | 0.527658 |
| PubMed Abstract | 0.744149 |
| Cancer Institute Cohort | 0.547453 |
| East West Highway | 0.542743 |
| International Agency | 0.53583 |
| Environmental Protection Agency | 0.819165 |
| probable carcinógeno | 0.619447 |
| Product Safety Commission | 0.830336 |
| among workers | 0.572581 |
| New Hampshire Avenue | 0.541693 |
|
| aislamiento uffi | 0.536299 |
| National Toxicology Program | 0.804784 |
| Drug Administration | 0.579636 |
| Environmental Health Sciences | 0.548429 |
| Occupational Environmental Medicine | 0.553867 |
| Mortality among | 0.531703 |
| Occupational Safety | 0.816569 |
| materiales aislantes | 0.528932 |
| British chemical workers | 0.549313 |
| Emergency Management Agency | 0.637566 |
| vÃas respiratorias | 0.526175 |
| National Cancer Institute | 0.733699 |
| National Institute | 0.579158 |
| aislamiento tipo uffi | 0.553887 |
| Health Administration | 0.662185 |
| Consumer Product Safety | 0.833221 |
| Indoor Environments Division | 0.548156 |
| corto plazo | 0.574665 |
| garment workers | 0.530046 |
| Blair A | 0.564637 |
| cabo estudios | 0.530631 |
| 12.º informe | 0.526826 |
| Federal Emergency Management | 0.627002 |
| Institutos Nacionales | 0.577211 |
|
CLICK HERE |
| 3445 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de cavidad oral y orofaringe (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de cavidad oral y orofaringe. |
| área pequeña detrás | 0.683574 |
| tratamiento causa efectos | 0.644315 |
| siguientes procedimientos | 0.606927 |
| Visuals Online | 0.549544 |
| PDQ Exámenes | 0.703056 |
| Physician Data Query | 0.843474 |
| prevención revisa | 0.561244 |
| siguientes tejidos | 0.858513 |
|
| PDQ Prevención | 0.768143 |
| cánceres ayuda | 0.626832 |
| información ayuda | 0.565771 |
| National Cancer Institute | 0.586864 |
| cáncer quizás | 0.965609 |
| siguientes riesgos | 0.571803 |
| siguientes sumarios | 0.718231 |
| Instituto Nacional | 0.660842 |
|
CLICK HERE |
| 15641 |
National Cancer Institute |
Html |
en |
Research Performance Progress Report (RPPR) |
Find more information about the RPPR, which documents recipient accomplishments and compliance with terms of award. |
| non-competing renewal | 0.483928 |
| public access policy | 0.676757 |
| NCI program | 0.46997 |
| business official | 0.461707 |
| grants management specialist | 0.511753 |
| Institutional Review Board | 0.501375 |
| recipient accomplishments | 0.470927 |
| progress reports | 0.710572 |
| budget period | 0.703772 |
| Performance Progress Report | 0.705145 |
| competing project period | 0.527715 |
| NCBI | 0.472549 |
| NIH staff | 0.493692 |
| Type 4s | 0.462417 |
| additional information | 0.516454 |
| email notification reminders | 0.504215 |
| award progress reports | 0.597891 |
| PubMed Central ID | 0.510154 |
| budget periods | 0.468611 |
| Progress Report Additional | 0.614182 |
| multiple PIs | 0.466396 |
| contact PI | 0.464615 |
| award process | 0.523874 |
| Management staff review | 0.506533 |
| final peer-reviewed journal | 0.498525 |
|
| grants management staff | 0.612225 |
| additional information online | 0.514579 |
| recipient wishes | 0.463817 |
| different schedule | 0.465588 |
| Institutional Animal Care | 0.498988 |
| annual progress reports | 0.586399 |
| progress report | 0.93768 |
| scientific progress | 0.590143 |
| subsequent budget period | 0.638937 |
| final progress report | 0.600792 |
| NIH applications | 0.499628 |
| eRA Commons | 0.829812 |
| full-text papers | 0.492864 |
| Non-competing continuation | 0.468466 |
| NCI staff | 0.465398 |
| Streamlined Noncompeting Award | 0.520709 |
| NIH funds | 0.496167 |
| NIH Public Access | 0.629563 |
| RPPR | 0.513098 |
| NIH funding | 0.492377 |
| Research Performance Progress | 0.694309 |
| Business Technology Transfer | 0.507309 |
| incomplete applications | 0.461976 |
| Small Business | 0.499434 |
|
CLICK HERE |
| 16826 |
National Cancer Institute |
Html |
en |
Early Onset Malignancies Initiative |
The Early Onset Malignancies Initiative studies the genomic basis of six cancers that develop at an earlier age, occur in higher rates, and are typically more aggressive in certain minority populations. |
| community sites | 0.48513 |
| control group | 0.496806 |
| certain minority populations | 0.77365 |
| exome sequencing | 0.513318 |
| ethnic populations | 0.59564 |
| ethnic groups | 0.477288 |
| multiple platforms | 0.483426 |
| early detection | 0.483135 |
| tumor behavior | 0.507221 |
| cutting-edge genomic characterization | 0.794697 |
| early age | 0.515521 |
| genomic datasets | 0.554094 |
| patient populations | 0.708455 |
| multiple myeloma | 0.479782 |
| critical research | 0.469762 |
| rich genomic data | 0.741156 |
| cancer types | 0.666255 |
| Thorough clinical data | 0.657553 |
| extensive data | 0.513023 |
| clinical measures | 0.479008 |
| molecular targets | 0.47719 |
| TCGA | 0.415616 |
| tumor progression | 0.525349 |
| earlier age | 0.508182 |
|
| higher rates | 0.504515 |
| important insights | 0.491579 |
| molecular drivers | 0.46961 |
| cancer type | 0.492461 |
| NCI Genome Characterization | 0.808398 |
| early disease | 0.497354 |
| clinical updates | 0.489197 |
| disease monitoring | 0.476658 |
| Genome Characterization Pipeline | 0.932301 |
| collaborative initiative | 0.505734 |
| NCI genomic characterization | 0.824673 |
| EOMI | 0.680345 |
| NCI Community Oncology | 0.754977 |
| total RNA sequencing | 0.668278 |
| underrepresented minorities | 0.53639 |
| Cancer Genome Atlas | 0.669216 |
| tissue samples | 0.659999 |
| Early Onset Malignancies | 0.747146 |
| EOMI data | 0.528397 |
| treatment response | 0.492799 |
| cancer risk | 0.496991 |
| genome sequencing | 0.549082 |
| Cancer Prevention | 0.5334 |
| normal tissue samples | 0.654735 |
|
CLICK HERE |